Beck took up his position at 4d in March, having previously held similar roles at three publicly-listed biotech groups during a thirty-year career.
“We are deeply saddened by John’s passing. The entire 4D pharma community mourns this loss and, on behalf of our board of directors and employees, we extend our sincerest condolences to his family,” said Duncan Peyton, chief executive.
“John’s 30 years of experience in the financial and biopharmaceutical industries were invaluable to us in his role as Chief Financial Officer, and his vision for the future of 4D pharma was already well on its way to being realized,” he added.
“We grieve this loss and will carry his legacy forward in this next chapter of 4D pharma continued growth and progress.”
4D pharma will continue to be actively led by its current management team and board of directors and succession planning is underway, said the statement.